New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 25, 2014
09:57 EDTSRPTSarepta CSO had 'serious disagreements' with CEO, WSJ reports
Sarepta's recently terminated Chief Scientific Officer Arthur Krieg said he had "serious disagreements" with CEO Chris Garabedian, Wall Street Journal reported last night, citing comments from a phone interview. Krieg's termination follows other management departures and "interrupts" the process" of preparing eteplirsen paperwork for the FDA, the Journal added, citing a person familiar with the matter. Recall that The Street's Adam Feuerstein reported yesterday that Krieg had no role in the clinical development of eteplirsen. Reference Link
News For SRPT From The Last 14 Days
Check below for free stories on SRPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 11, 2014
10:20 EDTSRPTNebraska Medical Center not naming Ebola drug, The Street reports
Nebraska Medical Center is not releasing the name of the experimental Ebola drug being given to Dr. Rick Sacra, The Street's Adam Feuerstein reports, citing an emailed response from the hospital. Traders are speculating Tekmira (TKMR) is the manufacturer of the drug, Feuerstein points out. Sarepta (SRPT) disclosed that it is not involved in the treatment of Sacra, added Feuerstein. Shares of Tekmira are up 3% to $19.65 in morning trading. Reference Link
September 4, 2014
13:17 EDTSRPTSarepta rises after FDA seeks comment on proposed DMD drug guidance
Subscribe for More Information
12:54 EDTSRPTSarepta strength attributed to circulation of DMD guidance document
Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use